Ancestral AAV Vector for Inner Ear Hair Cell Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene delivery methods have limited efficacy in targeting and transducing inner and outer hair cells in the inner ear, hindering effective gene therapy for genetic hearing loss and deafness, particularly for conditions like Usher Syndrome.
Innovation Solution
Development of a synthetic inner ear hair cell targeting adeno-associated virus (AAV) vector using an ancestral scaffold capsid protein, such as Anc80, which efficiently transduces both inner and outer hair cells, incorporating specific promoters to direct expression of polypeptides like TMC1, TMC2, and harmonin, achieving high transduction efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional gene delivery methods are used, then the process is simple and well-established, but the transduction efficiency of inner and outer hair cells is limited
Solution Approach 1:
The patent modifies the AAV capsid protein parameters by engineering ancestral scaffold proteins (Anc80L65, Anc90M33, Anc100L31) with specific amino acid sequences that enable efficient transduction of inner and outer hair cells. These parameter changes in the capsid structure fundamentally alter the vector's ability to target and transduce cochlear cells, resolving the contradiction between transduction efficiency and vector complexity.
Solution Approach 2:
The patent creates composite AAV vectors by combining ancestral scaffold capsid proteins with specific promoter elements (GFP, eGFP, tdTomato reporters) and polynucleotide cargo (TMC1, TMC2, MYO7A, PCDH15, SANS, CIB2). This composite structure integrates multiple functional components into a single vector system that achieves both high transduction efficiency and controlled gene expression in hair cells.
2Reliability
If existing AAV serotypes are used, then the vector system is well-characterized and safe, but the ability to efficiently target both IHCs and OHCs is insufficient
Solution Approach 1:
The engineered ancestral scaffold AAV vectors achieve universal transduction capability across multiple cell types in the inner ear, including both inner hair cells (IHCs) and outer hair cells (OHCs). The capsid proteins are designed to recognize and bind to receptors present on both cell types, enabling a single vector system to deliver therapeutic genes to diverse cochlear cell populations that conventional AAV serotypes could not efficiently transduce simultaneously.
3Productivity
If high transduction efficiency is achieved through engineered vectors, then therapeutic efficacy is improved, but the manufacturing complexity increases
Solution Approach 1:
The patent segments the AAV vector construction into modular components: ancestral scaffold capsid genes (Anc80L65, Anc90M33, Anc100L31), promoter regions, reporter genes (GFP, eGFP, tdTomato), and therapeutic polynucleotide cargo. This segmentation allows each component to be independently optimized, characterized, and manufactured, then assembled into complete vectors. The modular approach facilitates standardized production protocols and quality control, reducing manufacturing complexity despite the engineered nature of the vectors.
Data Source
AI summary
Provided herein are materials and methods for efficiently delivering nucleic acids to cochlear and vestibular cells, and methods of treating sensory transduction disorders associated with a genetic defect. Some embodiments are directed to a synthetic inner ear hair cell targeting adeno-associated virus (AAV) vector, a cell comprising the synthetic inner ear hair cell targeting AAV vector, and method of treating Usher Syndrome in a subject using the synthetic inner ear hair cell targeting AAV vector.